1
|
Kosiol J, Silvester T, Cooper H, Alford S, Fraser L. Revolutionising health and social care: innovative solutions for a brighter tomorrow - a systematic review of the literature. BMC Health Serv Res 2024; 24:809. [PMID: 38997711 PMCID: PMC11241933 DOI: 10.1186/s12913-024-11099-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Accepted: 05/10/2024] [Indexed: 07/14/2024] Open
Abstract
BACKGROUND In an era marked by rapid technological advancements, changing demographics, and evolving healthcare needs, the landscape of health services has been undergoing a profound transformation. Innovation has emerged as a central force driving change in the healthcare sector, as stakeholders across the globe strive to enhance the quality, accessibility, and efficiency of healthcare services. OBJECTIVE Within this dynamic context, this systematic literature review explored the barriers and driving forces behind successful health service innovation. METHODS A comprehensive systematic literature review was conducted using the Griffith University Library search engine and databases that included PubMed, ProQuest, Web of Science, Scopus, and CINHAL. To achieve the study goal, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the associated PRISMA checklist guided the review and reporting method. RESULTS Findings from this review identified a need for a universal definition of health innovation that encompasses the unique complexities and challenges within this context. In our comprehensive analysis of healthcare innovation, we have uncovered pivotal findings that underscore the indispensable nature of a well-structured framework. CONCLUSIONS To succeed in fostering innovation within the health and social care sectors, it is imperative to establish an overarching organisational culture that meticulously addresses the following key components: team challenges; communication and collaboration; governance goals and authentic leadership, environmental engagement; and innovation endurance. Through systematic analysis of existing literature, this review offers a definition of health innovation, covering its conceptual foundations, determinants, and barriers, and provides a framework for creating an innovative culture.
Collapse
Affiliation(s)
- Jennifer Kosiol
- Health Services Management, Griffith University, Brisbane, Australia.
| | - Tracey Silvester
- Health Services Management, Griffith University, Brisbane, Australia
| | - Helen Cooper
- Health Services Management, Griffith University, Brisbane, Australia
| | | | - Linda Fraser
- Health Services Management, Griffith University, Brisbane, Australia
| |
Collapse
|
2
|
Sullivan JA, Gold ER. Exploring regulatory flexibility to create novel incentives to optimize drug discovery. Front Med (Lausanne) 2024; 11:1379966. [PMID: 38808140 PMCID: PMC11131371 DOI: 10.3389/fmed.2024.1379966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Accepted: 04/17/2024] [Indexed: 05/30/2024] Open
Abstract
Efforts by governments, firms, and patients to deliver pioneering drugs for critical health needs face a challenge of diminishing efficiency in developing those medicines. While multi-sectoral collaborations involving firms, researchers, patients, and policymakers are widely recognized as crucial for countering this decline, existing incentives to engage in drug development predominantly target drug manufacturers and thereby do little to stimulate collaborative innovation. In this mini review, we consider the unexplored potential within pharmaceutical regulations to create novel incentives to encourage a diverse set of actors from the public and private spheres to engage in the kind of collaborative knowledge exchange requisite for fostering enhanced innovation in early drug development.
Collapse
Affiliation(s)
- Jacqueline A. Sullivan
- Department of Philosophy, Rotman Institute of Philosophy and Western Institute for Neuroscience, Western University, London, ON, Canada
| | - E. Richard Gold
- Faculty of Law and Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada
| |
Collapse
|
3
|
Resnik DB, Hosseini M. The Impact of AUTOGEN and Similar Fine-Tuned Large Language Models on the Integrity of Scholarly Writing. THE AMERICAN JOURNAL OF BIOETHICS : AJOB 2023; 23:50-52. [PMID: 37812101 PMCID: PMC10575681 DOI: 10.1080/15265161.2023.2250276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/10/2023]
|
4
|
Axtman AD, Brennan PE, Frappier‐Brinton T, Betarbet R, Carter GW, Fu H, Gileadi O, Greenwood AK, Leal K, Longo FM, Mangravite LM, Edwards AM, Levey AI. Open drug discovery in Alzheimer's disease. ALZHEIMER'S & DEMENTIA (NEW YORK, N. Y.) 2023; 9:e12394. [PMID: 37215505 PMCID: PMC10192886 DOI: 10.1002/trc2.12394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/12/2023] [Revised: 04/14/2023] [Accepted: 04/17/2023] [Indexed: 05/24/2023]
Abstract
Alzheimer's disease (AD) drug discovery has focused on a set of highly studied therapeutic hypotheses, with limited success. The heterogeneous nature of AD processes suggests that a more diverse, systems-integrated strategy may identify new therapeutic hypotheses. Although many target hypotheses have arisen from systems-level modeling of human disease, in practice and for many reasons, it has proven challenging to translate them into drug discovery pipelines. First, many hypotheses implicate protein targets and/or biological mechanisms that are under-studied, meaning there is a paucity of evidence to inform experimental strategies as well as high-quality reagents to perform them. Second, systems-level targets are predicted to act in concert, requiring adaptations in how we characterize new drug targets. Here we posit that the development and open distribution of high-quality experimental reagents and informatic outputs-termed target enabling packages (TEPs)-will catalyze rapid evaluation of emerging systems-integrated targets in AD by enabling parallel, independent, and unencumbered research.
Collapse
Affiliation(s)
- Alison D. Axtman
- University of North Carolina at Chapel HillChapel HillNorth CarolinaUSA
| | | | | | | | | | - Haian Fu
- Emory University School of MedicineAtlantaGeorgiaUSA
| | - Opher Gileadi
- Structural Genomics ConsortiumKarolinska InstituteStockholmSweden
| | | | | | - Frank M. Longo
- Stanford University School of MedicineStanfordCaliforniaUSA
| | | | - Aled M. Edwards
- Structural Genomics ConsortiumUniversity of TorontoTorontoOntarioCanada
| | | | | |
Collapse
|
5
|
Zhang L, Ma L. Is open science a double-edged sword?: data sharing and the changing citation pattern of Chinese economics articles. Scientometrics 2023; 128:2803-2818. [PMID: 37101973 PMCID: PMC10028759 DOI: 10.1007/s11192-023-04684-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Accepted: 03/05/2023] [Indexed: 03/24/2023]
Abstract
Data sharing is an important part of open science (OS), and more and more institutions and journals have been enforcing open data (OD) policies. OD is advocated to help increase academic influences and promote scientific discovery and development, but such a proposition has not been elaborated on well. This study explores the nuanced effects of the OD policies on the citation pattern of articles by using the case of Chinese economics journals. China Industrial Economics (CIE) is the first and only Chinese social science journal so far to adopt a compulsory OD policy, requiring all published articles to share original data and processing codes. We use the article-level data and difference-in-differences (DID) approach to compare the citation performance of articles published in CIE and 36 comparable journals. Firstly, we find that the OD policy quickly increased the number of citations, and each article on average received 0.25, 1.19, 0.86, and 0.44 more citations in the first four years after publication respectively. Furthermore, we also found that the citation benefit of the OD policy rapidly decreased over time, and even became negative in the fifth year after publication. In conclusion, this changing citation pattern suggests that an OD policy can be double edged sword, which can quickly increase citation performance but simultaneously accelerate the aging of articles.
Collapse
Affiliation(s)
- Liwei Zhang
- grid.27255.370000 0004 1761 1174School of Innovation and Entrepreneurship, Shandong University, 72 Binhai Road, Jimo District, Qingdao, Shandong Province 266237 China
| | - Liang Ma
- grid.24539.390000 0004 0368 8103School of Public Administration and Policy, Renmin University of China, 59 Zhongguancun Avenue, Haidian District, Beijing, 100872 China
| |
Collapse
|
6
|
Hennessy C, Deptula M, Hester J, Issa F. Barriers to Treg therapy in Europe: From production to regulation. Front Med (Lausanne) 2023; 10:1090721. [PMID: 36744143 PMCID: PMC9892909 DOI: 10.3389/fmed.2023.1090721] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Accepted: 01/03/2023] [Indexed: 01/20/2023] Open
Abstract
There has been an increased interest in cell based therapies for a range of medical conditions in the last decade. This explosion in novel therapeutics research has led to the development of legislation specifically focused on cell and gene based therapies. In Europe, the European medicines agency (EMA) designates any medicines for human use which are based on genes, tissues, or cells as advanced therapy medicinal products or advanced therapy medicinal products (ATMPs). In this article we discuss the hurdles to widespread adoption of ATMPs in Europe, with a focus on regulatory T cells (Tregs). There are numerous barriers which must be overcome before mainstream adoption of Treg therapy becomes a reality. The source of the cells, whether to use autologous or allogenic cells, and the methods through which they are isolated and expanded, must all meet strict good manufacturing practice (GMP) standards to allow use of the products in humans. GMP compliance is costly, with the equipment and reagents providing a significant cost barrier and requiring specialized facilities and personnel. Conforming to the regulations set centrally by the EMA is difficult, and the different interpretations of the regulations across the various member states further complicates the regulatory approval process. The end products then require a complex and robust distribution network to ensure timely delivery of potentially life saving treatments to patients. In a European market whose logistics networks have been hammered by COVID and Brexit, ensuring rapid and reliable delivery systems is a more complex task than ever. In this article we will examine the impact of these barriers on the development and adoption of Tregs in Europe, and potential approaches which could facilitate more widespread use of Tregs, instead of its current concentration in a few very specialized centers.
Collapse
Affiliation(s)
- Conor Hennessy
- Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom
| | - Milena Deptula
- Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom
- Laboratory of Tissue Engineering and Regenerative Medicine, Division of Embryology, Medical University of Gdańsk, Gdańsk, Poland
| | - Joanna Hester
- Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom
| | - Fadi Issa
- Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom
| |
Collapse
|
7
|
Ackloo S, Antolin AA, Bartolome JM, Beck H, Bullock A, Betz UAK, Böttcher J, Brown PJ, Chaturvedi M, Crisp A, Daniels D, Dreher J, Edfeldt K, Edwards AM, Egner U, Elkins J, Fischer C, Glendorf T, Goldberg S, Hartung IV, Hillisch A, Homan E, Knapp S, Köster M, Krämer O, Llaveria J, Lessel U, Lindemann S, Linderoth L, Matsui H, Michel M, Montel F, Mueller-Fahrnow A, Müller S, Owen DR, Saikatendu KS, Santhakumar V, Sanderson W, Scholten C, Schapira M, Sharma S, Shireman B, Sundström M, Todd MH, Tredup C, Venable J, Willson TM, Arrowsmith CH. Target 2035 – an update on private sector contributions. RSC Med Chem 2023. [DOI: 10.1039/d2md00441k] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/18/2023] Open
Abstract
Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging ‘open’ principles to develop a pharmacological tool for every human protein.
Collapse
Affiliation(s)
- Suzanne Ackloo
- Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada
| | - Albert A. Antolin
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain
| | | | - Hartmut Beck
- Research and Development, Bayer AG, Pharmaceuticals, 42103 Wuppertal, Germany
| | - Alex Bullock
- Center for Medicines Discovery, Old Road Campus, University of Oxford, Roosevelt Drive, Headington, Oxford, OX3 7DQ, UK
| | | | - Jark Böttcher
- Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
| | - Peter J. Brown
- Structural Genomics Consortium, University of North Carolina at Chapel Hill, USA
| | - Menorca Chaturvedi
- Boehringer Ingelheim International, Binger Str. 173, D-55216 Ingelheim, Germany
| | - Alisa Crisp
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, UK
| | - Danette Daniels
- Foghorn Therapeutics, 500 Technology Square, Suite 700, Cambridge, MA 02139, USA
| | - Jan Dreher
- Research and Development, Bayer AG, Pharmaceuticals, 42103 Wuppertal, Germany
| | - Kristina Edfeldt
- Structural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
| | - Aled M. Edwards
- Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada
| | - Ursula Egner
- Nuvisan Innovation Campus Berlin GmbH, Müllerstraße 178, 13353, Berlin, Germany
| | - Jon Elkins
- Center for Medicines Discovery, Old Road Campus, University of Oxford, Roosevelt Drive, Headington, Oxford, OX3 7DQ, UK
| | - Christian Fischer
- Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts 02115, USA
| | - Tine Glendorf
- Research & Early Development, Novo Nordisk A/S, Måløv, Denmark
| | - Steven Goldberg
- Janssen Research and Development LLC, San Diego, California, USA
| | - Ingo V. Hartung
- Medicinal Chemistry, Global R&D, Merck Healthcare KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany
| | - Alexander Hillisch
- Research and Development, Bayer AG, Pharmaceuticals, 42103 Wuppertal, Germany
| | - Evert Homan
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
| | - Stefan Knapp
- Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt 60438, Germany
- Structural Genomics Consortium, BMLS, Goethe University Frankfurt, Frankfurt 60438, Germany
| | - Markus Köster
- Boehringer Ingelheim International, Binger Str. 173, D-55216 Ingelheim, Germany
| | - Oliver Krämer
- Boehringer Ingelheim International, Binger Str. 173, D-55216 Ingelheim, Germany
| | - Josep Llaveria
- A Division of Janssen-Cilag S.A., Janssen Research and Development, Toledo, Spain
| | - Uta Lessel
- Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397 Biberach an der Riss, Germany
| | | | - Lars Linderoth
- Research & Early Development, Novo Nordisk A/S, Måløv, Denmark
| | - Hisanori Matsui
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Maurice Michel
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
| | - Florian Montel
- Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397 Biberach an der Riss, Germany
| | | | - Susanne Müller
- Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt 60438, Germany
- Structural Genomics Consortium, BMLS, Goethe University Frankfurt, Frankfurt 60438, Germany
| | - Dafydd R. Owen
- Discovery Network Group, Pfizer Medicine Design, Cambridge, MA 02139, USA
| | - Kumar Singh Saikatendu
- Global Research Externalization, Takeda California, Inc., 9625 Towne Center Drive, San Diego, CA 92121, USA
| | | | - Wendy Sanderson
- Janssen Research & Development, Janssen Pharmaceutica N. V, Beerse, Belgium
| | - Cora Scholten
- Research and Development, Bayer AG, Pharmaceuticals, 13353 Berlin, Germany
| | - Matthieu Schapira
- Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada
- Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada
| | - Sujata Sharma
- Janssen Research and Development LLC, San Diego, California, USA
| | - Brock Shireman
- Janssen Research and Development LLC, San Diego, California, USA
| | - Michael Sundström
- Structural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
| | - Matthew H. Todd
- School of Pharmacy, University College London, London, WC1N 1AX, UK
| | - Claudia Tredup
- Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt 60438, Germany
- Structural Genomics Consortium, BMLS, Goethe University Frankfurt, Frankfurt 60438, Germany
| | - Jennifer Venable
- Janssen Research and Development LLC, San Diego, California, USA
| | - Timothy M. Willson
- Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Cheryl H. Arrowsmith
- Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada
- Princess Margaret Cancer Centre, Toronto, Ontario, M5G 1L7, Canada
| |
Collapse
|
8
|
Kirwin E, Round J, Bond K, McCabe C. A Conceptual Framework for Life-Cycle Health Technology Assessment. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2022; 25:1116-1123. [PMID: 35779939 DOI: 10.1016/j.jval.2021.11.1373] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 11/11/2021] [Accepted: 11/23/2021] [Indexed: 05/06/2023]
Abstract
OBJECTIVES Health technology assessment (HTA) uses evidence appraisal and synthesis with economic evaluation to inform adoption decisions. Standard HTA processes sometimes struggle to (1) support decisions that involve significant uncertainty and (2) encourage continued generation of and adaptation to new evidence. We propose the life-cycle (LC)-HTA framework, addressing these challenges by providing additional tools to decision makers and improving outcomes for all stakeholders. METHODS Under the LC-HTA framework, HTA processes align to LC management. LC-HTA introduces changes in HTA methods to minimize analytic time while optimizing decision certainty. Where decision uncertainty exists, we recommend risk-based pricing and research-oriented managed access (ROMA). Contractual procurement agreements define the terms of reassessment and provide additional decision options to HTA agencies. LC-HTA extends value-of-information methods to inform ROMA agreements, leveraging routine, administrative data, and registries to reduce uncertainty. RESULTS LC-HTA enables the adoption of high-value high-risk innovations while improving health system sustainability through risk-sharing and reducing uncertainty. Responsiveness to evolving evidence is improved through contractually embedded decision rules to simplify reassessment. ROMA allows conditional adoption to obtain additional information, with confidence that the net value of that adoption decision is positive. CONCLUSIONS The LC-HTA framework improves outcomes for patients, sponsors, and payers. Patients benefit through earlier access to new technologies. Payers increase the value of the technologies they invest in and gain mechanisms to review investments. Sponsors benefit through greater certainty in outcomes related to their investment, swifter access to markets, and greater opportunities to demonstrate value.
Collapse
Affiliation(s)
- Erin Kirwin
- Institute of Health Economics, Edmonton, AB, Canada; Health Organisation, Policy, and Economics, School of Health Sciences, University of Manchester, Manchester, England, UK.
| | - Jeff Round
- Institute of Health Economics, Edmonton, AB, Canada; Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Ken Bond
- Institute of Health Economics, Edmonton, AB, Canada
| | - Christopher McCabe
- Institute of Health Economics, Edmonton, AB, Canada; Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| |
Collapse
|
9
|
Responsible artificial intelligence in agriculture requires systemic understanding of risks and externalities. NAT MACH INTELL 2022. [DOI: 10.1038/s42256-022-00440-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
10
|
Open and Crowd-Based Platforms: Impact on Organizational and Market Performance. SUSTAINABILITY 2022. [DOI: 10.3390/su14042223] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The aim of the research was to present the state of the art on the use of open and crowd-based platforms and the advantages in terms of business performance that emerging practices employing such technologies are able to provide. The analysis was performed by extracting information on emerging practices from the repository Business Process Framework for Emerging Technologies developed by the Department of Industrial Engineering of the University of Salerno (Italy). Contingency tables allowed analysis of the association of such practices with industry, business function, business process, and impact on performance. From the analysis of the results, many implementation opportunities emerge, mainly in manufacturing, healthcare, and transportation industries, providing benefits not only in terms of efficiency and productivity, cost reduction, and information management but also in product/service differentiation. Therefore, the research provides an overview of opportunities for organizations employing open and crowd-based platforms in order to improve market and organizational performance. Moreover, the article highlights in what specific business contexts these technologies can be mainly useful.
Collapse
|
11
|
He Z, Zhou T. A model for cooperative scientific research inspired by the ant colony algorithm. PLoS One 2022; 17:e0262933. [PMID: 35085346 PMCID: PMC8794102 DOI: 10.1371/journal.pone.0262933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Accepted: 01/09/2022] [Indexed: 11/22/2022] Open
Abstract
Modern scientific research has become largely a cooperative activity in the Internet age. We build a simulation model to understand the population-level creativity based on the heuristic ant colony algorithm. Each researcher has two heuristic parameters characterizing the goodness of his own judgments and his trust on literature. We study how the distributions of contributor heuristic parameters change with the research problem scale, stage of the research problem, and computing power available. We also identify situations where path dependence and hasty research due to the pressure on productivity can significantly impede the long-term advancement of scientific research. Our work provides some preliminary understanding and guidance for the dynamical process of cooperative scientific research in various disciplines.
Collapse
Affiliation(s)
- Zhuoran He
- School of Physics and Electronic Science, Hubei University, Wuhan, Hubei, China
- School of Physics, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Tingtao Zhou
- Division of Engineering and Applied Sciences, California Institute of Technology, Pasadena, CA, United States of America
| |
Collapse
|
12
|
Beck S, LaFlamme M, Bergenholtz C, Bogers M, Brasseur TM, Conradsen ML, Crowston K, Di Marco D, Effert A, Filiou D, Frederiksen L, Gillier T, Gruber M, Haeussler C, Hoisl K, Kokshagina O, Norn MT, Poetz M, Pruschak G, Pujol Priego L, Radziwon A, Ruser A, Sauermann H, Shah SK, Suess-Reyes J, Tucci CL, Tuertscher P, Vedel JB, Verganti R, Wareham J, Xu SM. Examining Open Innovation in Science (OIS): what Open Innovation can and cannot offer the science of science. INNOVATION-ORGANIZATION & MANAGEMENT 2021. [DOI: 10.1080/14479338.2021.1999248] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Susanne Beck
- Open Innovation in Science Center, Ludwig Boltzmann Gesellschaft, Vienna, Austria
- Department of Strategy and Innovation, Copenhagen Business School, Frederiksberg, Denmark
| | - Marcel LaFlamme
- Open Research, Public Library of Science, San Francisco, CA, USA
| | | | - Marcel Bogers
- Garwood Center for Corporate Innovation, Haas School of Business, University of California Berkeley, Berkeley, CA, USA
| | - Tiare-Maria Brasseur
- Open Innovation in Science Center, Ludwig Boltzmann Gesellschaft, Vienna, Austria
- Department of Strategy and Innovation, Copenhagen Business School, Frederiksberg, Denmark
| | | | - Kevin Crowston
- School of Information Studies, Syracuse University, Syracuse, NY, USA
| | | | - Agnes Effert
- Open Innovation in Science Center, Ludwig Boltzmann Gesellschaft, Vienna, Austria
| | - Despoina Filiou
- Department for Strategy and Marketing, The Open University Business School, Milton Keynes, UK
| | - Lars Frederiksen
- Department of Management, Aarhus BSS, Aarhus University, Aarhus, Denmark
| | - Thomas Gillier
- Department of Management, Technologies and Strategies, Grenoble Ecole de Management, Grenoble, France
| | - Marc Gruber
- College of Management of Technology, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Carolin Haeussler
- School of Business, Economics and Information Systems, University of Passau, Passau, Germany
| | - Karin Hoisl
- Department of Strategy and Innovation, Copenhagen Business School, Frederiksberg, Denmark
- Business School, University of Mannheim, Mannheim, Germany
| | - Olga Kokshagina
- EDHEC Business School, 24 Av. Gustave Delory, 59100 Roubaix, France
| | - Maria-Theresa Norn
- Danish Centre for Studies on Research and Research Policy, Department of Political Science, Aarhus Bss, Aarhus University, Aarhus C, Denmark
| | - Marion Poetz
- Open Innovation in Science Center, Ludwig Boltzmann Gesellschaft, Vienna, Austria
- Department of Strategy and Innovation, Copenhagen Business School, Frederiksberg, Denmark
| | - Gernot Pruschak
- Business School, Bern University of Applied Sciences, Bern, Switzerland
| | | | - Agnieszka Radziwon
- Garwood Center for Corporate Innovation, Haas School of Business, University of California Berkeley, Berkeley, CA, USA
- Department of Business Development and Technology, Aarhus BSS, Aarhus University, Herning, Denmark
| | - Alexander Ruser
- Department of Sociology & Social Work, University of Agder, Kristiansand, Norway
| | | | - Sonali K. Shah
- Department of Business Administration, Gies College of Business, University of Illinois at Urbana-Champaign, Champaign, IL, USA
| | - Julia Suess-Reyes
- Open Innovation in Science Center, Ludwig Boltzmann Gesellschaft, Vienna, Austria
- Department of Strategy and Innovation, Copenhagen Business School, Frederiksberg, Denmark
| | - Christopher L. Tucci
- Imperial College Business School, Imperial College London, South Kensington Campus, London, UK
| | - Philipp Tuertscher
- School of Business and Economics, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Jane Bjørn Vedel
- Department of Organization, Copenhagen Business School, Frederiksberg, Denmark
| | - Roberto Verganti
- House of Innovation, Stockholm School of Economics, Stockholm, Sweden
| | | | - Sunny Mosangzi Xu
- Department of Food and Resource Economics, University of Copenhagen, Frederiksberg, Denmark
| |
Collapse
|